Revolutionizing Drug Discovery With High-throughput Screening

By Author: Snehal S
Total Articles: 396
Comment this article

Introduction
The high-throughput screening market refers to the industry involved in the development and commercialization of technologies, instruments, and services for the high-throughput screening of compounds in drug discovery and other life science research applications. High-throughput screening is a process that enables the rapid and automated testing of large numbers of chemical or biological compounds for their ability to interact with biological targets of interest, such as enzymes, receptors, or DNA.

Global High-Throughput Screening Market Overview
The global high-throughput screening (HTS) market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.

The high-throughput screening (HTS) market growth is driven mainly by factors such as increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments. Emerging markets and growing applications in life sciences research ...
... are also factors expected to provide growth opportunities for players in the market.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

MARKET DRIVERS
• The growing adoption of open innovation models in pharmaceutical & biotechnology companies
• Government funding and venture capital investments
• Increasing R&D spending
• Technological advancements in the HTS market
MARKET RESTRAINTS
• The capital-intensive nature of HTS instruments
• Complexities in assay development
MARKET OPPORTUNITIES
• Emerging markets
• Growing applications in stem cell research
MARKET CHALLENGES
• The dearth of skilled operators

Market Segmentation:

On the basis type of product & service, the HTS Market is broadly segmented into consumables , instruments, services, and software. In 2019, consumables accounted for the largest share of the high-throughput screening (HTS) market. This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R&D, and rising government funding for life sciences research.

Based on application, the HTS Market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications. The drug discovery application segment accounted for the largest share of the market in 2019. The key factor driving this segments growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure.

Regional Analysis:
In 2019, Asia Pacific region accounted for the fastest-growing region of the HTS Market. It is also estimated to grow at the highest CAGR in the market during the forecast period, this is mainly due to factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the market in this region.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950

Recent Developments
• In 2020, Danaher Corporation (US) acquired the biopharma business of General Electric Company (Cytiva) to expand its presence in the high-throughput screening market.
• In 2019, Agilent Technologies, Inc. (US) acquired BioTek Instruments (US) to expand its presence and expertise in cell analysis. This development also strengthened the firm’s position in the expansive immune-oncology and immunotherapy areas.
• In 2019, Danaher Corporation (US) acquired Labcyte Inc. (US) to expand its liquid handling and laboratory automation business, thereby strengthening its presence in the high-throughput screening market.

Top Key Players: -
Some of the prominent players in the high-throughput screening market are Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Group Ltd. (Switzerland), AXXAM S.p.A. (Italy), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Corning Incorporated (US), and Eurofins Scientific (Luxembourg).

Conclusion:
In conclusion, the high-throughput screening market has grown significantly in recent years, driven by the increasing demand for more efficient and cost-effective drug discovery methods. High-throughput screening technologies enable researchers to quickly and accurately test large numbers of compounds for their efficacy, toxicity, and other characteristics, which can accelerate the drug development process and improve the chances of success in clinical trials. Advances in automation, robotics, and data analysis have further improved the speed and accuracy of high-throughput screening, making it an essential tool in modern drug discovery. With continued investment and innovation, the high-throughput screening market is expected to grow further, enabling the development of new and more effective treatments for a wide range of diseases.